In Section C, members will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until condition progression or even the contributors are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit merchandise within three times prior to https://abbv-744-drug-development91245.ltfblog.com/31072312/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled